Nigel McCracken
Chief Tech/Sci/R&D Officer at BERGENBIO ASA
Profile
Nigel McCracken is currently the Chief Scientific Officer at BerGenBio ASA and the Chief Operating Officer at Virax Biolabs Group Ltd.
He previously worked as the Executive Director & VP-Translational Medicine at Debiopharm International SA from 2014 to 2019.
He also held a position as COO and Senior VP-Discovery & Early Development at NuCana Plc.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and his graduate degree from King's College London.
Nigel McCracken active positions
Companies | Position | Start |
---|---|---|
BERGENBIO ASA | Chief Tech/Sci/R&D Officer | 31/12/2020 |
VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 31/08/2023 |
Former positions of Nigel McCracken
Companies | Position | End |
---|---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 31/03/2019 |
NUCANA PLC | Chief Operating Officer | - |
Training of Nigel McCracken
University of Strathclyde | Undergraduate Degree |
King's College London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
BERGENBIO ASA | Health Technology |
NUCANA PLC | Health Technology |
VIRAX BIOLABS GROUP LIMITED | Finance |
Private companies | 1 |
---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Nigel McCracken